Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

amredobresib

An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential antineoplastic activity. Upon oral administration, amredobresib binds to bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) as well as bromodomain testis-specific protein (BRDT), thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and suppresses the expression of certain oncogenes, including Myc and other transcriptional regulators. Preventing the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.
Synonym:BET inhibitor BI 894999
Code name:BI 894999
BI-894999
BI894999
Chemical structure:1,2,4-triazolo(4,3-a)pyrazin-8-amine, N,3-dimethyl-6-(6-(4-methyl-1-piperazinyl)-1-(phenylmethyl)-1hbenzimidazol-2-yl)
6-(1-benzyl-6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl)-N,3-dimethyl-(1,2,4)triazolo(4,3-a)pyrazin-8-amine
Search NCI's Drug Dictionary